← Arbutus Biopharma Corp
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($384.2m) |
($84.4m)
+78.03%
|
($57.1m)
+32.40%
|
($153.7m)
-169.41%
|
($63.7m)
+58.53%
|
($76.2m)
-19.61%
|
($69.5m)
+8.91%
|
($72.8m)
-4.89%
|
($69.9m)
+4.02%
|
($33.5m)
+52.09%
|
— | |
| Net Income (Loss) Available to Common Stockholders, Basic | — | ($85.3m) |
($67.2m)
+21.30%
|
($164.9m)
-145.52%
|
($75.9m)
+53.98%
|
($88.4m)
-16.50%
|
($69.5m)
+21.42%
|
— | — | — | — | |
| Depreciation | $1.1m | $2.0m | $2.2m | $2.0m | $2.0m | $1.8m | $1.4m | $1.4m | $1.4m | $363k | $44k | |
| Deferred Income Tax Expense (Benefit) | ($105.1m) | ($24.3m) | ($4.3m) | ($12.7m) | $0 | — | — | — | — | — | — | |
| Share-based Payment Arrangement, Noncash Expense | — | — | $6.2m | $6.8m | $6.2m | $6.4m | $7.2m | $9.3m | $9.0m | $7.0m | $4.7m | |
| Share-based Payment Arrangement, Expense | $39.2m | $15.1m | $6.0m | $6.8m | $6.2m | $6.4m | $7.2m | $9.3m | $9.0m | $7.0m | $4.7m | |
| Goodwill and Intangible Asset Impairment | $391.3m | — | — | — | — | — | — | — | — | — | — | |
| Goodwill, Impairment Loss | $138.2m | $0 | $0 | $22.5m | $0 | — | — | — | — | — | $0 | |
| Impairment of Intangible Assets (Excluding Goodwill) | $253.2m | $40.8m | $14.8m | $43.8m | $0 | — | — | — | — | — | — | |
| Income (Loss) from Equity Method Investments | — | — | ($5.6m) | — | ($2.5m) | $0 | — | — | — | — | — | |
| Nonoperating Income (Expense) | $2.5m | $2.2m | $28.4m | ($22.3m) | ($5.9m) | ($2.7m) | $444k | $5.3m | $6.4m | $4.7m | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | ($735k) | $129k | $1.0m | ($227k) | $108k | ($413k) | $453k | $424k | $633k | ($1.4m) | $1.3m | |
| Net Cash Provided by (Used in) Operating Activities | ($57.9m) |
($48.6m)
+15.97%
|
($67.9m)
-39.53%
|
($71.0m)
-4.63%
|
($51.4m)
+27.55%
|
($67.5m)
-31.28%
|
($35.4m)
+47.65%
|
($85.9m)
-143.06%
|
($64.8m)
+24.54%
|
($39.6m)
+38.88%
|
($34.4m)
+13.32%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $4.0m | $7.3m | $1.1m | $589k | $229k | $809k | $512k | $1.0m | $182k | $0 | ($182k) | |
| Gain (Loss) on Disposition of Property Plant Equipment | ($174k) | $3k | $26k | ($20k) | $0 | — | — | $20k | $0 | $674k | ($674k) | |
| Cash, Cash Equivalents, and Short-term Investments | $130.6m | $126.4m | $124.6m | — | $123.3m | $191.0m | $184.3m | $132.3m | $122.6m | $91.5m | — | |
| Debt Securities, Realized Gain (Loss) | — | — | — | — | — | — | $100k | $100k | $100k | $100k | — | |
| Gain (Loss) on Investments | — | — | $24.9m | — | — | — | — | — | — | — | — | |
| Payments to Acquire Investments | — | — | — | $58.8m | $85.6m | $82.2m | $130.4m | $80.5m | $141.5m | $140.1m | ($119.1m) | |
| Net Cash Provided by (Used in) Investing Activities | ($99.1m) | $27.8m | ($4.1m) | $28.3m | ($14.9m) | ($12.7m) | ($74.9m) | $50.8m | $22.9m | $15.6m | $6.4m | |
| Cash flows from financing activities: | ||||||||||||
| Proceeds from Issuance of Long-term Debt | $12.0m | $0 | — | — | — | — | — | — | — | — | — | |
| Proceeds from Issuance of Common Stock | $0 | $0 | — | $18.6m | $86.3m | $134.7m | — | — | — | — | $0 | |
| Net Cash Provided by (Used in) Financing Activities | $12.6m |
$49.3m
+290.27%
|
$55.6m
+12.82%
|
$37.5m
-32.69%
|
$86.7m
+131.59%
|
$137.2m
+58.20%
|
$31.8m
-76.82%
|
$30.6m
-3.67%
|
$52.0m
+69.66%
|
$5.7m
-89.00%
|
$14.6m
+154.43%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | — | $20.5m | $57.0m | ($78.5m) | ($4.5m) | $10.0m | ($18.3m) | $23.7m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $52.3m | $109.3m | $30.8m | $26.3m | $36.3m | $18.0m | $23.7m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | — | $56k | $5k | ($22k) | $25k | ($49k) | $14k | $0 | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $192k | $100k | $1.4m | $307k | $449k | $2.1m | $122k | $260k | $7.5m | $5.5m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | $0 | — | — | — | — | — | — | — | |
| Additional Financial Items | ||||||||||||
| Fair Value, Option, Changes in Fair Value, Gain (Loss) | $530k | ($22k) | $0 | — | — | — | — | — | — | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | $1.1m | $2.3m | ($1.0m) | $41k | ($124k) | $5k | ($22k) | $25k | ($49k) | $14k | — | |
| Foreign Currency Transaction Gain (Loss), Unrealized | $1.0m | $2.4m | ($1.0m) | $68k | $56k | $5k | — | — | — | — | — | |
| General and Administrative Expense | $39.4m | $16.1m | $16.0m | $17.7m | $14.7m | $17.1m | $17.8m | $22.5m | $22.1m | $15.9m | — | |
| Goodwill | $24.4m | $24.4m | $22.5m | $0 | — | — | — | — | — | — | $0 | |
| Income Tax Expense (Benefit) | ($105.0m) | ($24.3m) | ($4.3m) | ($12.7m) | $0 | $0 | $4.4m | $0 | $0 | $0 | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $137k | $97k | — | |
| Investment Income, Interest | $1.4m | $1.5m | $3.0m | $2.1m | $741k | $127k | $2.2m | $5.7m | $6.6m | $4.1m | — | |
| Operating Expenses | $493.1m | $121.6m | $95.7m | $150.1m | $64.7m | $84.5m | $104.5m | $96.2m | $82.5m | $52.2m | — | |
| Operating Lease, Expense | — | — | — | $1.2m | $700k | $700k | $700k | — | — | — | — | |
| Restructuring Costs | — | — | $396k | $0 | — | — | — | — | — | — | — |